BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
As the Covid-19 pandemic sweeps the world, cancer research is proving a valuable resource for…
Sofinnova Partners, Europe’s largest VC focused on life sciences, has raised €333M to fund early-stage…
The French company Innate Pharma has raised a Nasdaq IPO of €62.1M ($68.8M) to fund…
A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating…
Innate Pharma and MedImmune will test the combination of Innate’s cancer antibody and the checkpoint…
As 2016 was a tough year for biotech, 2017 was under pressure to turn things…
Novo Nordisk has handed over its anti-cancer antibody to Innate Pharma in a new deal…
Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances…
While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for…
Innate Pharma's checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial,…
From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's…